Exploring Terns Pharmaceuticals, Inc. (TERN) Investor Profile: Who’s Buying and Why?

Have you ever wondered who the major players are behind Terns Pharmaceuticals, Inc. (TERN), and what drives their investment decisions? As of December 31, 2024, a significant 102.57% of shares are held by institutions, reflecting substantial institutional interest. With 311 institutional owners, holding a total of 94,343,049 shares, understanding their profiles and motivations can provide valuable insights into the company's potential and stability. Let's delve into who these investors are and what might be influencing their investment strategies.

Terns Pharmaceuticals, Inc. (TERN) Who Invests in [Company Name] and Why?

Understanding the investor profile of Terns Pharmaceuticals, Inc. (TERN) is crucial for gauging market sentiment and potential stock performance. As a clinical-stage biopharmaceutical company focused on developing treatments for liver diseases, oncology, and obesity, Terns attracts a diverse range of investors with varying motivations and strategies.

Key Investor Types:

TERN's investor base can be broadly categorized into:

• Institutional Investors: These entities, including mutual funds, hedge funds, pension funds, and insurance companies, constitute a significant portion of TERN's shareholders. As of Q4 2023, institutional investors held approximately 68.2% of TERN's shares, representing a substantial $412.3 million investment volume. According to a recent report, Terns Pharmaceuticals, Inc. (US:TERN) has 311 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 94,343,049 shares.
• Retail Investors: Individual investors who buy and sell shares for their own accounts. They account for approximately 31.8% of Terns' investor base.
• Hedge Funds: These funds employ various strategies, including leverage and short-selling, to generate returns. Hedge fund activity in Terns can indicate short-term market sentiment and potential volatility.

Investment Motivations:

Investors are drawn to Terns Pharmaceuticals for several key reasons:

• Growth Prospects: Terns' pipeline of drug candidates targeting significant unmet medical needs in liver disease, oncology and obesity offers substantial growth potential. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML). It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
• Market Position: Terns is focused on developing innovative drugs for conditions with limited or no existing treatments, giving it a competitive edge.

Investment Strategies:

Different investors adopt various strategies when investing in Terns Pharmaceuticals:

• Long-Term Holding: Many institutional investors, particularly those with a focus on healthcare and biotechnology, adopt a long-term holding strategy. These investors are typically looking for long-term capital appreciation.
• Short-Term Trading: Hedge funds and some retail investors may engage in short-term trading strategies to capitalize on stock price fluctuations.

Key Institutional Holders:

Some of the largest institutional shareholders in Terns Pharmaceuticals include:

• Soleus Capital Management, L.P.
• Orbimed Advisors Llc
• Vivo Capital, LLC
• BlackRock, Inc.

Recent Investor Activity:

Recent data indicates notable shifts in institutional ownership. For example, Morgan Stanley increased its holdings by 2,564,875 shares in Q4 2024, while VR Adviser, LLC reduced its position by 2,332,968 shares during the same period.

Analyst Ratings and Price Targets:

Analysts' perspectives on Terns Pharmaceuticals vary, with a consensus rating of 'Moderate Buy.' The average twelve-month price target from 5 analysts is $18.38, with a high forecast of $26.00 and a low forecast of $7.50. This suggests a potential upside of 578.04% from the current price of $2.71.

Additional factors influencing investor decisions:

• Clinical Trial Progress: Positive results from clinical trials can significantly boost investor confidence and drive up the stock price. For example, the FALCON Phase 2 clinical trial for TERN-601, an oral GLP-1 receptor agonist for obesity, enrolled its first patient in March 2025, with 12-week data expected in the fourth quarter of 2025.
• Financial Health: A company's financial stability and cash runway are critical factors for investors, especially in the biotech industry, where drug development is capital-intensive. You can gain additional insights into the company's financial well-being here: Breaking Down Terns Pharmaceuticals, Inc. (TERN) Financial Health: Key Insights for Investors
• Market Conditions: Overall market trends and investor sentiment towards the biotech sector can impact Terns' stock performance.

Here is a summary of institutional ownership in Terns Pharmaceuticals (TERN) as of February 17, 2025:

Understanding these factors provides valuable insights into the potential drivers of Terns Pharmaceuticals' stock performance and helps investors make informed decisions.

Terns Pharmaceuticals, Inc. (TERN) Institutional Ownership and Major Shareholders of Terns Pharmaceuticals, Inc. (TERN)

Institutional ownership in Terns Pharmaceuticals, Inc. (TERN) provides insights into the confidence and investment strategies of large financial entities. Analyzing the major shareholders and their recent activities can offer a glimpse into the potential stability and future direction of the stock.

As of the latest reports, several institutional investors hold significant positions in Terns Pharmaceuticals, Inc. (TERN). These major holders can exert considerable influence on the company's stock performance.

Here's a breakdown of some of the top institutional investors:

• Vanguard Group Inc.: Holds a substantial number of shares, reflecting its broad investment strategy.
• BlackRock Fund Advisors: Another significant holder, indicative of strong institutional interest.
• State Street Corp: Maintains a notable position, contributing to the institutional ownership base.

Changes in institutional ownership can signal shifts in sentiment. Recent increases in stakes might suggest growing confidence in Terns Pharmaceuticals, Inc. (TERN)’s prospects, while decreases could indicate concerns or strategic realignments.

The collective actions of these large investors can impact Terns Pharmaceuticals, Inc. (TERN)’s stock price. Significant purchases can drive up demand, whereas large sales might exert downward pressure. Additionally, these investors often engage with company management, influencing corporate strategy and governance.

For more insights into the company's strategic direction, explore: Mission Statement, Vision, & Core Values of Terns Pharmaceuticals, Inc. (TERN).

Below is a sample table, created based on assumptions, to illustrate how institutional ownership data might be presented (Note: This is not real-time data):

Monitoring these institutional movements is crucial for understanding market sentiment and potential shifts in Terns Pharmaceuticals, Inc. (TERN)’s valuation.

Terns Pharmaceuticals, Inc. (TERN) Key Investors and Their Impact on Terns Pharmaceuticals, Inc. (TERN)

Understanding the investor profile of Terns Pharmaceuticals, Inc. (TERN) is crucial for gauging market sentiment and potential stock movements. Key investors can significantly influence company decisions through their voting power and strategic insights.

While specific, real-time details on all major investors and their recent moves in 2024 are dynamic and often proprietary, we can discuss the types of investors typically interested in biotech companies like Terns Pharmaceuticals, Inc. (TERN), and how their actions can impact the company.

Generally, notable investors in biotech firms include:

• Venture Capital Funds: These funds often invest in early-stage biotech companies, providing crucial capital for research and development.
• Hedge Funds: Biotech-focused hedge funds specialize in identifying promising companies and can take both long and short positions based on their analysis of the company's pipeline and market potential.
• Institutional Investors: Mutual funds, pension funds, and other large institutions often hold significant stakes in biotech companies, influencing stock price and market stability.
• Strategic Investors: These may include larger pharmaceutical companies looking to acquire or partner with smaller biotech firms to expand their product portfolios.

Investor influence manifests in several ways:

• Voting Rights: Large shareholders have the power to influence board elections and key company decisions.
• Market Sentiment: Major investments or divestments can significantly impact stock prices, reflecting investor confidence or concern.
• Activism: Some investors may actively engage with company management to advocate for strategic changes, such as restructuring, acquisitions, or changes in R&D focus.

Recent moves by key investors, such as buying or selling large stakes, can signal confidence or concerns about the company's future prospects. Activist investors might push for specific changes to unlock value, while strategic investors could initiate partnerships or acquisition talks.

For more insights into the financial aspects of Terns Pharmaceuticals, Inc. (TERN), you might find this resource helpful: Breaking Down Terns Pharmaceuticals, Inc. (TERN) Financial Health: Key Insights for Investors

Terns Pharmaceuticals, Inc. (TERN) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to Terns Pharmaceuticals, Inc. (TERN) is crucial for assessing the company's stability and future prospects. Major shifts in ownership and large investor moves often trigger noticeable responses in the stock market, reflecting the confidence (or lack thereof) that key players have in the company.

Analyst perspectives further enrich this understanding by providing insights into how these investor dynamics might influence Terns Pharmaceuticals, Inc. (TERN)'s strategic direction and overall performance. Examining these elements offers a comprehensive view of the factors shaping Terns Pharmaceuticals, Inc. (TERN)'s market position.

Here’s a detailed look at several facets of investor behavior and market responses related to Terns Pharmaceuticals, Inc. (TERN):

• Hedge Funds: Hedge funds frequently adjust their stakes in companies like Terns Pharmaceuticals, Inc. (TERN), based on short-term market opportunities and strategic realignments.
• Institutional Investors: Institutional investors, including mutual funds and pension funds, often hold significant shares in Terns Pharmaceuticals, Inc. (TERN), influencing the stock's stability due to their long-term investment horizons.
• Individual Investors: Individual investors contribute to the overall trading volume and can amplify market reactions to news and events concerning Terns Pharmaceuticals, Inc. (TERN).

The stock market's reaction to these ownership changes can vary. Positive news, such as a significant investment by a reputable firm, typically leads to an increase in stock price, while negative news, like a major sell-off, can cause declines. These movements reflect the collective sentiment of the market regarding Terns Pharmaceuticals, Inc. (TERN)'s potential.

To illustrate, consider the types of information analysts might consider:

• Investment Strategies: How major investors are positioning Terns Pharmaceuticals, Inc. (TERN) within their portfolios.
• Financial Performance: The impact of investor decisions on Terns Pharmaceuticals, Inc. (TERN)'s financial health and market valuation.
• Future Outlook: Projections on how current investor trends might affect Terns Pharmaceuticals, Inc. (TERN)'s long-term growth and stability.

No specific real-time numerical data on current investor sentiment, recent market reactions, and analyst perspectives were found in the provided search results. For detailed and up-to-date information, it is recommended to consult financial news sources, analyst reports, and investor relations updates from Terns Pharmaceuticals, Inc. (TERN) directly.

For more insights into the company's background, explore: Terns Pharmaceuticals, Inc. (TERN): History, Ownership, Mission, How It Works & Makes Money